Celyad Competitors and Similar CompaniesClear all
Celyad's competitors and similar companies include Bellicum Pharmaceuticals, Alnylam, Sorrento Therapeutics and Moderna.
 Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Bellicum Pharmaceuticals Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. | |
Founding Date | Founding Date 2007 | Founding Date 2004 | Founding Date 2002 | Founding Date 2006 | Founding Date 2010 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations Houston, US HQ Houston, US Houston, US South San Francisco, US | Locations San Diego, US HQ San Diego, US | ||
Employees | Employees 17 | Employees 1386% increase | Employees 1,32324% increase | Employees 31019% decrease | Employees 5,60044% increase |
Valuation ($) | Valuation ($) 11.8 m | Valuation ($) 778.3 k | Valuation ($) 36.5 b | Valuation ($) 1.5 m | Valuation ($) 21.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $1.5m (FY, 2022) | Revenue (est.) $2.2b (FY, 2024) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $3.2b (FY, 2024) |
Cost of goods | Cost of goods €69k (FY, 2023) | Cost of goods N/A | Cost of goods $306.5m (FY, 2024) | Cost of goods N/A | Cost of goods $1.5b (FY, 2024) |
Gross profit | Gross profit €1.4m (FY, 2023) | Gross profit N/A | Gross profit $1.9b (FY, 2024) | Gross profit N/A | Gross profit $1.8b (FY, 2024) |
Net income | Net income (€8.4m) (FY, 2023) | Net income ($25m) (FY, 2022) | Net income ($278.2m) (FY, 2024) | Net income ($577.8m) (FY, 2022) | Net income ($3.6b) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 1.5b | Total funding raised $ 42.6m | Total funding raised $ 1.8b |
For sources of this data, please see the company profile
View Company Profiles
Bellicum Pharmaceuticals
HQ
Houston, US
Employees
13
Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyModerna
HQ
Cambridge, US
Employees
5,600↑ 44% increase
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
View company